Pink Sheet Podcast: Election Fallout, IRA Impacting Product Development, Updated US FDA Expanded Access Policy

Pink Sheet reporters and editor discuss the impact of the midterm elections, the Inflation Reduction Act’s effects on drug development, and adjustments to FDA expanded access guidance.

Pink Sheet podcast
Will the new Congress attempt to change the drug price negotiation provisions of the Inflation Reduction Act? • Source: Pink Sheet illustration

Pink Sheet senior writers Derrick Gingery and Sarah Karlin-Smith, and Executive Editor Nielsen Hobbs discuss the impact of the midterm elections on the US Food and Drug Administration and health care policy, how sponsors are making product development decisions based on the Inflation Reduction Act’s price negotiation provisions, and new guidance addressing stakeholders’ expanded access questions.

Open Media

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Elections

More from Legislation